Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637189 | 0.97 | LMNA (0.35) | SMN1; SMN2CA1CA2LMNAALDH1A1 | |
| SCHEMBL8671685 | 0.97 | LMNA (0.35) | SMN1; SMN2CA1CA2LMNAALDH1A1 | |
| SCHEMBL6849263 | 0.97 | LMNA (0.35) | SMN1; SMN2CA1CA2LMNAALDH1A1 | |
| SCHEMBL879892 | 0.97 | LMNA (0.35) | SMN1; SMN2CA1CA2LMNAALDH1A1 | |
| SCHEMBL6852245 | 0.97 | LMNA (0.35) | SMN1; SMN2CA1CA2LMNAALDH1A1 | |
| SCHEMBL338407 | 0.97 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL2780201 | 0.88 | — | — | |
| SCHEMBL2245008 | 0.84 | GAA (0.39) | MEN1KMT2ATSHRCYP4F2CYP4A11 | |
| SCHEMBL6650821 | 0.84 | — | — | |
| SCHEMBL2096698 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111792985-A | Fluorine-containing heat transfer fluid and preparation method and application thereof | 北京宇极科技发展有限公司 | 2020-10-20 | — | — | CN | claimed |
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| CN-119684140-A | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-115175894-B | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| CN-116887841-A | Nanomaterials comprising ester-linked acetals | 比姆医疗股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023174773-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| EP-4103542-A1 | NANOMATERIALS | Guide Therapeutics, LLC (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-114874106-A | Amino lipid and preparation method and application thereof | 中山大学附属第七医院(深圳) | 2022-08-09 | — | — | CN | disclosed |
| US-20070142443-A1 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1685092-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | Takasago International Corporation (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-20060122418-A1 | Method for producing an optically active beta-amino acid | MATSUMURA KAZUHIKO | 2006-06-08 | — | — | US | disclosed |
| US-7015348-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| WO-2005028419-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-03-31 | — | — | WO | disclosed |
| US-20040023344-A1 | Method for producing an optically activ beta-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-0225574-B1 | NOVEL 1,4-DIHYDROPYRIDINES CONTAINING FLUORINE, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BAYER AG (DE) | 1990-05-16 | — | — | EP | disclosed |
| US-4798840-A | Coronary-active fluorine-containing 1,4-dihydropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1989-01-17 | — | — | US | disclosed |
| EP-0225574-A1 | Novel 1,4-dihydropyridines containing fluorine, process for their preparation and their use as medicaments | BAYER AG (DE) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | SMN1; SMN2 1183/4885CA1 2972/4885CA2 2179/4885 |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | LIPA, SGMS1, SGMS2 | SMN1; SMN2 575/4885CA1 788/4885CA2 4139/4885 |
| US-20070142443-A1 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | AADAT, BCAT2, BCAT1 | SMN1; SMN2 4356/4885CA1 712/4885CA2 1358/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | SMN1; SMN2 1417/4885CA1 2550/4885CA2 2977/4885 |
| US-20060122418-A1 | Method for producing an optically active beta-amino acid | AADAT, DAO, BCAT2 | SMN1; SMN2 3286/4885CA1 1014/4885CA2 706/4885 |
| US-20070073065-A1 | Substituted optically active disphosphine compound | DHPS, DOHH, DHODH | SMN1; SMN2 4805/4885CA1 1750/4885CA2 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.